Synergistic Malaria Prevention and Treatment System
Legal Citation
Summary of the Inventive Concept
A novel system integrating recombinant MVA viral vectors with AI, IoT, blockchain, and nanomaterial technologies to provide a more effective and efficient approach to preventing and treating malaria.
Background and Problem Solved
The original patent disclosed recombinant MVA viral vectors for generating an immune response to malaria. However, the patent's limitations include the lack of a comprehensive system for predicting optimal vaccine composition, monitoring vaccine distribution, and tracking environmental factors contributing to malaria transmission. The new inventive concept addresses these limitations by combining the patented viral vectors with AI-powered analysis, blockchain-based tracking, IoT sensors, and nanomaterial-based adjuvants.
Detailed Description of the Inventive Concept
The Synergistic Malaria Prevention and Treatment System consists of a recombinant MVA viral vector vaccine, an AI-powered analysis module for predicting optimal vaccine composition, a blockchain-based tracking system for monitoring vaccine distribution and administration, and IoT sensors for monitoring environmental factors contributing to malaria transmission. The system may also incorporate nanomaterial-based adjuvants to enhance vaccine efficacy. The AI-powered analysis module uses machine learning algorithms to analyze patient data and predict optimal treatment regimens. The blockchain-based tracking system ensures secure and transparent monitoring of vaccine distribution and administration.
Novelty and Inventive Step
The new inventive concept's novelty lies in the integration of distinct technologies, including AI, IoT, blockchain, and nanomaterials, with the patented recombinant MVA viral vectors to create a more powerful system for preventing and treating malaria. The inventive step is the synergistic combination of these technologies to provide a comprehensive solution that addresses the limitations of the original patent.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include using different types of viral vectors, such as adenovirus or lentivirus, or incorporating additional technologies, such as CRISPR-Cas9 gene editing or synthetic biology. Variations of the system may focus on specific aspects, such as AI-powered predictive analytics or blockchain-based supply chain management.
Potential Commercial Applications and Market
The Synergistic Malaria Prevention and Treatment System has significant commercial potential in the global healthcare market, particularly in regions where malaria is prevalent. The system's ability to provide a comprehensive solution for preventing and treating malaria makes it an attractive option for governments, NGOs, and private healthcare organizations.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/015 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K47/6901 |
| A | A61 | A61P33/06 |
| A | A61 | A61K2039/5256 |
| A | A61 | A61K2039/54 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Vaccine development, immunology, and infectious disease prevention, with specialized expertise in recombinant viral vector technologies, particularly for malaria prevention
Person of Ordinary Skill (PHOSITA) Profile
A researcher or scientist with advanced degrees in molecular biology, immunology, or virology, possessing expertise in viral vector design, vaccine development, and computational biology techniques
Obviousness Rationale
A PHOSITA would recognize that integrating computational and tracking technologies with existing viral vector vaccine platforms represents a predictable extension of current vaccine development strategies. The combination of AI, blockchain, and IoT technologies with the established MVA viral vector approach provides a logical progression in vaccine delivery and monitoring. The technical elements proposed in the PTD represent incremental improvements that would be obvious to a skilled practitioner seeking to enhance vaccine efficacy and distribution.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,611 |
|---|---|
| Title | Compositions and methods for generating an immune response to treat or prevent malaria |
| Assignee(s) | GeoVax, Inc. |